DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

November 30, 2004

Conditions
Meningeal Neoplasms
Interventions
DRUG

Intrathecal (injected into the spinal fluid) DepoCyt

DRUG

Intrathecal methotrexate

DRUG

Intrathecal cytarabine (also known as ara-C)

Trial Locations (23)

15213

University of Pittsburgh Cancer Institute, Pittsburgh

20007

Georgetown University Medical Center Hematology/Oncology, Washington D.C.

27157

Bowman Gray School of Medicine/Comprehensive Cancer Center of Wake Forest University, Winston-Salem

30322

Emory Clinic, Department of Neurosurgery, Atlanta

32224

Mayo Clinic, Jacksonville, Jacksonville

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37232

Vanderbilt University Medical Center, Nashville

44106

Case Western Reserve University Hospital of Cleveland, Cleveland

55416

Park Nicollet Institute, Oncology Research Program, Minneapolis

60153

Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood

60612

Rush Cancer Institute, Chicago

78284

University of Texas Health Science Center, San Antonio

80010

University of Colorado Hospital, Anschutz Cancer Pavilion, Denver

84112

University of Utah, Hunsman Cancer Institute, Salt Lake City

85013

Barrow Neurological Institute, Phoenix

90033

University of Southern California, Norris Cancer Center, Los Angeles

94704

Alta Bates Comprehensive Cancer Center, Berkeley

96813

Straub Clinic and Hospital, Honolulu

98101

Virginia Mason Medical Center, Seattle

02215

Beth Israel Deaconess Medical Center Dept. of Neurology, Boston

08820

JFK Neuroscience Institute, Edison

R3E0V9

CancerCare Manitoba, Winnipeg

M4N3M5

Toronto Sunnybrook Regional Cancer Center, Toronto

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY